About Equashield
Equashield is a company based in New York (United States) founded in 2009 by Eric Shem Tov and Marino Kriheli. Equashield has raised $300 million across 1 funding round from investors including Nordic Capital. The company has 14 employees as of April 06, 2024. Equashield operates in a competitive market with competitors including ICU Medical, Carmel Pharma, Corvida Medical and Simplivia, among others.
- Headquarter New York, United States
- Employees 14 as on 06 Apr, 2024
- Founders Eric Shem Tov, Marino Kriheli
- Stage Unicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Equashield Llc
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$154.91 K (USD)2.44as on Mar 31, 2023
-
Net Profit
-$18.6 K (USD)-4093.6as on Mar 31, 2023
-
EBITDA
-$14.24 K (USD)-274.16as on Mar 31, 2023
-
Total Equity Funding
$300 M (USD)
in 1 rounds
-
Latest Funding Round
$300 M (USD), Series D
Oct 06, 2022
- Investors
-
Employee Count
14
as on Apr 06, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Equashield
Equashield has successfully raised a total of $300M through 1 strategic funding round. The most recent funding activity was a Series D round of $300 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Equashield
Equashield has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Nordic Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Equashield
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Equashield
Investment portfolio details for Equashield
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Equashield
Detailed financials for Equashield
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Equashield Comparisons
Peer comparison for Equashield
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Equashield
Equashield operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ICU Medical, Carmel Pharma, Corvida Medical and Simplivia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug and Infusion delivery devices
|
|
| Locked | Locked | Locked |
Closed-system transfer devices are produced for safe hazardous drug handling.
|
|
| Locked | Locked | Locked |
Closed system transfer device for safe administration of hazardous drugs
|
|
| Locked | Locked | Locked |
Manufactures closed system transfer devices to protect healthcare workers from drug exposure.
|
Detailed competitors of Equashield
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Equashield
Complete news archive for Equashield
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Equashield
Equashield was founded in 2009 and raised its 1st funding round 13 years after it was founded.
Equashield is headquartered in New York, United States. It is registered at New York, New York, United States.
Eric Shem Tov is the current CEO of Equashield. They have also founded this company.
Equashield is a funded company, having raised a total of $300M across 1 funding round to date.
As of Apr 06, 2024, the latest employee count at Equashield is 14.
Annual revenue of Equashield is $154.91K as on Mar 31, 2023.
Equashield was founded in 2009 and is based in New York, United States. Operations focus on the healthcare sector, where closed-system transfer devices are developed for managing hazardous drugs. The EQUASHIELD Pro automated compounding robot is utilized to prepare individual doses, ensuring accuracy while reducing errors in medication and dosage. Exposure risks to healthcare workers from hazardous drugs and vapors are mitigated through these systems.
Equashield's top competitors include ICU Medical, Carmel Pharma and Corvida Medical.
Equashield has 1 investor. Key investors include Nordic Capital.
The valuation of Equashield is $1.3B as of Oct 2022.